Wednesday, June 10, 2026

Patent intelligence · WO

WO 2021152186

ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES

granted A61K/31337A61K/31555A61K/31704A61K/393955
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 24
Patent details — WO 2021152186
Jurisdiction
WO
Status
granted
Grant date
Aug 5, 2021
Expiration
Jul 31, 2041
Applicant
BAYER AG [DE]
CPC classes
A61K/31337, A61K/31555, A61K/31704, A61K/393955
View on Google Patents ↗

Quick answer

WO 2021152186 (ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES) is held by BAYER AG [DE]. Status: granted. Granted Aug 5, 2021. Expires Jul 31, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
BAYER AG [DE]
Grant date
Expiration
Claims
CPC classes
A61K/31337, A61K/31555, A61K/31704, A61K/393955, A61K/4506, A61K/476849

More from BAYER AG [DE]

Related pharmaceutical patents in our USPTO index.

  1. WO 2024052517

    USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE

    BAYER AG [DE] · Expires Mar 9, 2044

    granted
  2. CN 117186084

    Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus

    BAYER HEALTHCARE AG · Expires Dec 3, 2043

    granted
  3. CN 115348859

    Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate

    BAYER HEALTHCARE AG · Expires Nov 10, 2042

    granted
  4. CN 115003329

    Parapoxvirus for conditioning and treating coronavirus infections

    BAYER HEALTHCARE AG · Expires Aug 28, 2042

    granted
  5. BR 112021015776

    Edição de gene para hemofilia a com expressão de fator viii melhorada

    BAYER HEALTHCARE LLC [US] · Expires Nov 4, 2041

    granted
  6. DE 102019218587

    Kontrastmittelbasierte Gefäßdarstellung

    BAYER AG [DE] · Expires May 28, 2041

    granted
  7. DE 102019218589

    Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen

    BAYER AG [DE] · Expires May 28, 2041

    granted

Frequently asked questions

What is US patent 2021152186?

WO 2021152186 (ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES) is held by BAYER AG [DE]. Status: granted. Granted Aug 5, 2021. Expires Jul 31, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2021152186?

BAYER AG [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.

When does WO 2021152186 expire?

Our index shows an expiration date of Jul 31, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.